Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.…
Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio (NASDAQ: TIL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 5.230 USD on 20 November 2026, down 65.2% over 52 weeks. Its 52-week range is 5.170 USD to 16.00 USD: the price is 67.3% below the high and 1.2% above the low.
Its market capitalisation is 35.47M USD.
Instil Bio reports return on equity of -62.7% and an operating margin of 0.0%.
Its debt exceeds its cash by 17.74M USD, a debt-to-equity ratio of 0.75. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Hold; their mean price target of 7.000 USD is 33.8% above the current price.